Pharvaris (PHVS) Non Operating Income (2021 - 2026)
Pharvaris' (PHVS) quarterly Non Operating Income came in at $6.3 million in Q1 2026, up 254.43% YoY from $1.8 million in Q1 2025, and up 113.12% on a QoQ basis from $2.9 million in Q4 2025.
Pharvaris (PHVS) Non Operating Income (2021 - 2026) Analysis & Trends
Pharvaris (PHVS) has 6 years of Non Operating Income data on file, last reported at $6.3 million in Q1 2026.
- Quarterly Non Operating Income rose 254.43% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 32.57% YoY) and the FY2025 annual result came in at -$4.4 million, down 130.54% from the prior year.
- Non Operating Income climbed to $6.3 million in Q1 2026, from $2.9 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $12.4 million in Q4 2024 to a low of -$26.9 million in Q4 2022.
- A 5-year average of $1.0 million and a median of $2.7 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income surged 644.52% — and 2025, when it sank 745.01%.
- Tracing PHVS's Non Operating Income over 5 years: stood at -$26.9 million in 2022, then surged by 91.55% to -$2.3 million in 2023, then jumped by 644.52% to $12.4 million in 2024, then tumbled by 76.25% to $2.9 million in 2025, then jumped by 113.12% to $6.3 million in 2026.
- The last three Non Operating Income figures came in at $6.3 million (Q1 2026), $2.9 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | 4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.12 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.74 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Mar 31, 2025 | -4.05 Mn |
| Dec 31, 2024 | 12.36 Mn |
| Sep 30, 2024 | -3.93 Mn |
| Jun 30, 2024 | 5.08 Mn |
| Mar 31, 2024 | 628,156.10 |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 709,619.36 |
| Mar 31, 2023 | -1.60 Mn |
| Dec 31, 2022 | -26.88 Mn |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 12.27 Mn |
| Mar 31, 2022 | 3.81 Mn |
| Dec 31, 2021 | -8,692.92 Bn |
| Sep 30, 2021 | 5.02 Mn |